Cancer cell secretion of TGF-β is a potent mechanism for immune evasion. However, little is known about how central nervous system tumors guard against immune eradication. We sought to determine the impact of T-cell TGF-β signaling blockade on progression of medulloblastoma (MB), the most common pediatric brain tumor. Genetic abrogation of T-cell TGF-β signaling mitigated tumor progression in the smoothened A1 (SmoA1) transgenic MB mouse. T regulatory cells were nearly abolished and antitumor immunity was mediated by CD8 cytotoxic T lymphocytes. To define the CD8 T-cell subpopulation responsible, primed CD8 T cells were adoptively transferred into tumor-bearing immunocompromised SmoA1 recipients. This led to generation of CD8 + / killer cell lectin-like receptor G1 high (KLRG1 hi )/IL-7R lo short-lived effector cells that expressed granzyme B at the tumor. These results identify a cellular immune mechanism whereby TGF-β signaling blockade licenses the T-cell repertoire to kill pediatric brain tumor cells.
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cancer immunology | neuroimmunology | neuro-oncology C NS tumors are the leading cause of death among pediatric cancer patients, and medulloblastoma (MB) is the most common pediatric CNS malignancy (1) . Following surgical resection, these patients require aggressive multimodal therapy, resulting in long-term treatment-related complications, including developmental, neurological, neuroendocrine, and psychosocial deficits (1) (2) (3) . Variants of MB have been defined (e.g., classic, desmoplastic, anaplastic, and extremely nodular) pathologically and by gene expression profiling (4) (5) (6) (7) . Approximately one third of all MBs are characterized by up-regulation of genes in the Sonic hedgehog (Shh) pathway and are predominantly desmoplastic (5, 7, 8) . Constitutive activation of the Shh pathway typically results from mutations in the Shh receptor [Patched (Ptc)] or downstream Smoothened (Smo), leading to hyperproliferation of granule neuron precursors (GNPs) and tumorigenesis (5, 8, 9) . Smoothened A1 (SmoA1) transgenic mice harbor a Smo activating mutation under regulatory control of the CNS specific neuronal differentiation 2 (Neurod2) promoter, which drives expression in GNPs (10) (11) (12) . These animals have constitutively active Shh signaling in the cerebellum, resulting in highly penetrant MB (10) .
Although the CNS was once thought to be excluded from immune surveillance, CNS neoplasms are now known to affect local and systemic immune responses (13, 14) . Patients with brain tumors often present with T-cell lymphopenia (15) (16) (17) , an immunodeficiency condition that promotes tumor growth and recurrence (18) . Despite the presence of tumor infiltrating lymphocytes (TILs), the immune response to CNS tumors is severely impaired (15, 17) . This phenomenon is at least partly a result of tumor secretion of immunosuppressive cytokines such as TGF-β (16, 17, 19) , a pleiotropic cytokine that dampens responses of innate and adaptive immune cells (20, 21) . In particular, TGF-β can block differentiation of naïve T cells into T helper (T h ) CD4, and CD8 cytotoxic T lymphocytes (CTLs) (22) (23) (24) (25) . Because they are chiefly responsible for antitumor immunity, evasion of CTLs is critical for tumor survival.
TGF-β is also involved in the generation and function of T regulatory cells (T regs ) (26, 27) , which suppress physiological and pathological immune responses and prevent autoimmune disease (28) (29) (30) . Interestingly, previous studies have shown greater immunosuppressive activity of T regs associated with CNS tumors (31) (32) (33) . The transcription factor Foxp3 plays a crucial role in immune homeostasis and T reg development (34) (35) (36) , as demonstrated by the dramatic autoimmune phenotype of the Foxp3 forkhead domain-deficient Scurfy mouse (37) , and autoimmune disease in humans bearing Foxp3 mutations known as immunodysregulation polyendocrinopathy enteropathy X-linked syndrome. Foxp3 expression itself is regulated by cooperative activation of multiple transcription factors by cytokine receptors, including the TGF-β receptor (26, (38) (39) (40) (41) . Specifically, TGF-β receptor binding causes the transcription factors Smad3 and nuclear factor of activated T cells (NFAT) to promote Foxp3 expression through histone acetylation at one of two known enhancer elements (26) . Therefore, oversecretion of TGF-β by CNS tumors can potentially undermine effective antitumor immunity by stimulating Foxp3 + T regs (42, 43) . To determine the role of TGF-β T-cell immunosuppression in MB progression, we used transgenic mice with blockade of T-cell TGF-β signaling. These mice express a dominant-negative (DN) form of TGF-β receptor type II under CD4 promoter regulatory Significance Medulloblastoma (MB) is a tumor of the cerebellum that primarily forms in pediatric patients during brain development. The immune system ultimately fails to eradicate MB because it is "blind" to tumor cells as a result of poor brain immune surveillance caused by the existence of the blood-brain barrier and the brain's immune privileged status. Another mechanism of tumor escape is immune suppressors that act as a "smokescreen," blocking effective antitumor immunity. We show that blockade of the TGF-β signaling pathway promotes memory T cell development, conferring antitumor immunity to the smoothened A1 mouse model of MB. Our data lay the cellular immune mechanistic framework for blocking T cell TGF-β signaling in pediatric brain cancer.
control (TGF-βRII-DN). This DN retains the extracellular and transmembrane domains, but has a truncated intracellular kinase domain, thereby allowing it to outcompete endogenous receptors for TGF-β ligands (23) . Because this construct lacks the CD8 silencer, the transgene is expressed by CD4 and CD8 T cells (44) . We crossbred TGF-βRII-DN and SmoA1 animals, and demonstrate that blockade of T-cell TGF-β signaling promotes CD8 Tcell differentiation into killer cell lectin-like receptor G1 high (KLRG1 hi )/IL-7R lo short-lived effector cells (SLECs), which militate against MB progression. Furthermore, CD8 T cells derived from tumor-bearing TGF-βRII-DN +
/SmoA1
+ mice are efficient tumor cell serial killers in vitro and in vivo. In this scenario, CTL antitumor immunity can be propagated from one animal to another when adoptively transferred into tumor-bearing Rag2
+ hosts. These results show how TGF-β signaling affects adaptive immunity in the fight against pediatric brain cancer.
Results
T regs Infiltrate TGF-β-Producing Human MBs. TGF-β ligand is initially synthesized as a precursor protein that undergoes proteolysis. The mature, dimeric form of TGF-β is composed of two ∼12.5-kDa monomers stabilized by hydrophobic interactions and disulfide bonds, forming a protein of 25 kDa that initiates intracellular signaling (45) . We Western blotted for TGF-β in MB samples, control pediatric cerebral cortex, and glioma tissue homogenates. Precursor TGF-β protein was detected in all nine MB samples assayed, and there was approximately eightfold greater abundance of this protein vs. control cortical and glioma tissue by densitometry (Fig. 1A) . Interestingly, MB samples contained similar monomeric TGF-β abundance as control glioma tissue, which was not detected in control cerebral cortex (Fig. 1A) . The mature, dimeric form of TGF-β was found in five of nine MBs, but was not detected in cortical or glioma tissue (Fig. 1A) . There was no relationship between TGF-β1 abundance and MB subtype.
Next, we investigated whether human MB-infiltrating CD4 T cells expressed TGF-β signaling components. Immunohistochemistry (IHC) and confocal imaging were carried out on freshly isolated human malignant MB tissue biopsies using CD4 and TGF-βRII antibodies. CD4 T cells expressed TGF-βRII at the cell surface (Fig. 1B) , and coexpression of TGF-β1 ligand and TGF-βRII was frequently observed (Fig. 1C) . CD4
+ TGF-βRII + T cells lacked nuclear expression of the MB/GNP-enriched transcription factor Zic1 (46) (Fig. 1D ), indicating that CD4 + TGF-βRII + cells were not CNS-derived. Collectively, these results suggest that human MB-infiltrating T cells express canonical TGF-β signaling machinery. To ascertain whether T regs (defined by Foxp3 and CD25 positivity) were present in human MBs, flow cytometric analyses were carried out on single cell suspensions generated from seven primary human MB samples.
Interestingly, Foxp3
+ cells represented ∼5-10% of CD25 + T cells in human MBs (Fig. 1 D and E) .
T regs Are Present in Shh-Driven Mouse MB. Shh pathway mutations are thought to drive MB (4, 8, 9, 47) . The Shh ligand undergoes autocatalytic processing and modification that is critical for signaling activity. Specifically, the 45-kDa precursor protein is cleaved to yield a 19-kDa N-terminal signaling domain (Shh-N) and a 25-kDa C-terminal domain (48) . By using an Shh-N antibody, Shh precursor protein was detected in 10 of 11 human MBs and the N-terminal signaling domain was found in 9 of 11 samples (Fig. S1A) . Shh-N binds to a multicomponent receptor complex containing Ptc (a 12-pass transmembrane protein) and Smo (a seven-transmembrane G protein-coupled receptor). Binding of Shh to Ptc releases basal repression of Smo; therefore, Smo activity is widely used as a surrogate for Shh pathway activation (49-51). We detected the higher molecular weight, activated form of Smo in all human MB samples (Fig. S1A) . Interestingly, control pediatric cortex tissue contained Shh precursor, yet lacked detectable Shh-N protein (Fig. S1) . Moreover, whereas Shh-N was observed in control human glioma tissue, activated Smo was not (Fig. S1 ), likely because Shh does not drive forebrain oncogenesis (52) . Significantly higher activeto-inactive Smo ratios were detected in each of the desmoplastic MB samples (Fig. S1 ), the form of human MB most often associated with Shh pathway oncogenesis (4, 8) . Collectively, these results indicate that Shh pathway activity is elevated in multiple human MB variants.
Active Smo and Shh signaling in human MB samples prompted investigation into whether SmoA1 + mouse MBs contained T regs . We hypothesized that this might be the case because tumor-bearing SmoA1 mice had elevated dimeric, mature TGF-β1 compared with tumor-free mice of the same genotype ( Fig. 2A) . To determine this, we bred SmoA1 animals with mice coexpressing Foxp3 and EGFP under endogenous regulatory control (Foxp3 EGFP mice) (53, 54) . This mouse strain has normal Foxp3 and T reg function (53) , and was used to detect T regs during the primary immune response to MB. As Foxp3 is located on the X chromosome, random X-inactivation results in fewer circulating EGFP +
CD4
+ T cells of heterozygous females vs. hemizygous males. Therefore, males were separately analyzed from females. 
Foxp3
EGFP+ cells that predominantly localized to germinal centers (Fig. S2A ). These data were verified by flow cytometric analysis of T-cell receptor (TCR)α/β gated splenocytes; and there was ∼2.5-fold increased splenic T regs in both male and female Foxp3 EGFP /SmoA1 + animals ( Fig. S2 B and C).
T-Cell TGF-β Signaling Blockade Mitigates MB Progression in SmoA1
Mice. To assess the impact of abrogating T-cell TGF-β signaling on MB progression, we bred TGF-βRII-DN + with SmoA1 + mice and performed survival analyses. Animals were followed for 10 mo, and TGF-βRII-DN + /SmoA1 + mice survived ∼40% better than SmoA1 + littermates (Fig. 3A) . (Fig. 4 A and B) . These IHC results were further (Fig. 4D) . We also found increased proportions of splenocytes in TGF-βRII-DN + /SmoA1 + mice that expressed TCRα/β at early (5 mo of age; Fig. 5A ) and late stages (10 mo of age) of tumor growth (Fig. S3) . Furthermore, splenocytes from TGF-βRII-DN + /SmoA1 + mice at both ages had increased CD8 and CD4 T-cell effector memory (T EM ) and central memory (T CM ) populations and reduced naïve T cells compared with appropriate controls ( Fig. 5 B and C and Fig. S3 ). Similar results were observed in thymocytes from the same animals (Fig. S4) . Further confirmation of enhanced T-cell memory in TGF-βRII-DN + /
SmoA1
+ mouse spleens came from increased expression of CD44, T-bet, and STAT3 phosphorylation by Western blot (Fig. 5D ). 
/SmoA1
+ TILs (Fig. 6E ) and splenocytes (Fig. S5 ). These cells also expressed higher amounts of the CTL markers IFN-γ and CD45 (Fig. 6E) . Together, these results indicate that blocking T-cell TGF-β signaling during MB malignancy promotes CD8 T-cell differentiation into SLECs and MPECs. (Fig. 7A) . We then established a cell line from SmoA1 + mouse MB. These cells express Zic1 and neural stem cell markers Sox2 and Nestin under neural stem cell growth conditions (Fig. S6A) . Additionally, these cells are capable of differentiating into neurons that express neuronal nuclei (NeuN) antigen or neuron-specific class III β-tubulin (Tuj1) and also into glial fibrillary acidic protein (Gfap)-positive astrocytes (Fig. S6 B  and C) . This cell line was used to measure granzyme B (Gran B)-mediated CD8 T-cell killing. In this assay (55) 
+ mice were more efficient serial killers vs. appropriate controls (Fig. 7 B and C) . Strikingly, live confocal microscopy and 3D surface rendering showed active CD8 T-cell killing of MB target cells (Fig. 7D and Movie S1).
CD8 T Cell Antitumor Immunity Can Be Propagated in Vivo. Our next goal was to address whether the TGF-βRII-DN transgene alone was sufficient to endorse CTL activity in mouse MBs, or whether previous exposure to MB was additionally required. To achieve this, CD8 T cells isolated from tumor-bearing IL-7Rα hi populations and express IFN-γ and CD45. Leukocytes were pooled from three tumor-bearing mice per genotype (*P < 0.05 and ***P < 0.001). (Fig. 8A) . To measure CTL activity, we performed confocal microscopy on brain sections immunostained with antibodies against CD8, Gran B, and Zic1. These data revealed enhanced CTL activity in TGF-βRII-DN + T cells isolated from tumor-bearing TGF-βRII-DN +
+ hosts as readout qualitatively and quantitatively by Gran B immunoreactivity surrounding donor CD8 T cells in Zic1 + tumors (Fig. 8 B and C) . These results demonstrate that anti-MB immunity can be propagated by primed TGF-β signaling-inhibited CD8 T cells.
Discussion
In this report, we show that blockade of T-cell TGF-β signaling directs expansion and activation of CTLs against MB. Specifically, blockade of this signaling pathway during MB malignancy promotes memory T-cell formation, conferring antitumor immunity. A previous study demonstrated that TGF-β functions in vivo to limit CD8 T-cell expansion and activation after highaffinity peptide-MHC interactions (56) . Here, we have shown that human and mouse MBs abundantly produce TGF-β, making these tumors well-suited to evade CTL immune surveillance. Indeed, our results indicate that TGF-β-mediated immunosuppression endorses MB malignancy. Interestingly, it has been shown that TGF-β signaling controls CD8 effector T cell numbers by lowering Bcl-2 abundance and by selectively promoting apoptosis of SLECs (57) . These results dovetail with ours; collectively suggesting that TGF-β-mediated apoptosis of T-cell subpopulations likely regulates clonal expansion and contraction during immune responses to CNS malignancies.
Presence of the TGF-βRII-DN transgene drastically reduced Foxp3 + CD25 + T regs in SmoA1 + MB mice. In tumor-bearing Foxp3 EGFP /SmoA1 + mice, these cells were negative for the naturally occurring T reg marker neuropilin-1 (58) (Fig. S7) , suggesting that they were induced T regs (iT regs ). Multiple recent reports have elucidated the molecular mechanisms leading to TGF-β-mediated Foxp3 induction in iT regs in a variety of disease settings (41, 59, 60) . By using a Foxp3 reporter, our data support that TGF-β is required for T reg homing to mouse MBs. These T regs critically rely on Foxp3 expression and likely function to suppress antitumor T effector function. The regulatory regions for Foxp3 consist of a promoter, two enhancers and a conserved noncoding sequence region. At the enhancer 1 region, Smad3 and NFAT coordinately induce Foxp3 (26), leading to iT reg differentiation via signals through TCR and TGF-β receptors (26, 40, 41) . Elevated STAT3 activity in TGF-βRII-DN
+ animals may also explain reduced T reg numbers, as Foxp3 enhancer 2 activity is negatively regulated by STAT3. Given changes in T reg and CD8 T-cell populations, it is likely that disruption of TGF-β signaling serves a dual role in promoting the development of T effector responses by (i) limiting iT reg activity and (ii) promoting expansion and activation of CD8 T cells. This paradigm is summarized in Fig. S8 .
Although it is important to recognize that mouse models do not always predict human disease biology, data presented in this report provide a mechanistic framework for a pharmacotherapeutic strategy aimed at blocking T-cell TGF-β signaling in pediatric brain cancer. Specifically, we have shown that human MBs contain high abundance of TGF-β1 and T cells expressing TGF-βRII. A likely possibility is that MBs secrete TGF-β1 to evade T-cell-mediated antitumor immunity. The results herein demonstrate the role that TGF-β plays to dampen CTL responses to mouse MB. This TGF-β-dependent balance between T regs and CTLs is paramount when considering immunotherapeutic approaches against these devastating childhood tumors.
Materials and Methods
Mice. C57BL/6-Tg(Neurod2-SmoA1) mice (10) Tissue Handling. Adult mice (5 or 10 mo of age) were killed with isoflurane and perfused intracardially with ice-cold PBS solution. Brains were dissected down the midline and fixed for 24 h in 4% (wt/vol) paraformaldehyde (PFA), rinsed, and embedded in 2% (wt/vol) agarose. Tissue was sectioned in the sagittal plane on a Leica VT1200S Vibratome at 70-μm thickness and applied to Superfrost Plus Gold slides (Fisher Scientific). Fresh human samples were immediately frozen on dry ice and stored at −80°C for protein isolation or separately fixed for 24 h in 4% (wt/vol) PFA, rinsed, and embedded in 2% (wt/vol) agarose for IHC. IHC and Histology. For IHC, coverslips or sections were incubated in protein block (PBS solution containing 10% (vol/vol) FBS and 0.3% Triton X-100) for 1 h at 25°C. Antibodies to the following proteins were variously used: rat antihuman CD4 (1:500; Thermo Scientific), goat anti-TGF-βRII (1:500; R&D Systems), rabbit anti-human TGF-β1 (1:1,000; Torrey Pines Biolabs), rabbit anti-human/mouse Zic-1 (1:500; Rockland), chicken anti-GFP (1:5,000; Abcam), mouse anti-mouse CD4 (1:200; Thermo Scientific), rat anti-mouse CD25 (1:200; eBioscience), rat anti-mouse CD45 (AbD Serotec), chicken anti-mouse Nestin (1:2,000; LifeSpan Biosciences), goat anti-mouse Sox2 (Santa Cruz), mouse anti-mouse NeuN (1:1,000; Millipore), mouse anti-mouse Tuj1 (1:500; Covance), and rabbit anti-mouse Gfap (1:2,000; Dako). Antibodies were diluted in protein block and incubated overnight at 4°C. After three rinses for 5 min each in PBS solution, samples were incubated for 1 h at 25°C with appropriate Alexa Fluor-conjugated secondary antibodies. After an additional three rinses for 5 min each with PBS solution at 25°C, samples were air-dried in the dark and mounted with Prolong Gold media containing DAPI (Invitrogen-Molecular Probes). Fluorophores were imaged in separate channels with a Nikon A1R confocal microscope mounted onto a Ti-E inverted system equipped with a 40×/1.3 oil immersion Apochromat objective. For bright-field histology, nuclei were stained with alum hematoxylin for 4 min, rinsed in tap water, reacted with 0.3% acid alcohol, rinsed, and then stained with eosin for 2 min, rinsed, and mounted.
Hindbrains were imaged at 20× using a Leica SCN 400 slide scanner. Biochemical Analysis. Human tissue or mouse spleen samples was homogenized using a T10 basic Homogenizer (IKA Works). All samples were lysed in cell lysis buffer (Cell Signaling) containing 1 mM PMSF and subjected to Western immunoblot. Protein concentration was determined by using the bicinchoninic acid method, and an aliquot corresponding to 50 μg of protein was electrophoretically separated on 12% (wt/vol) Nu-PAGE polyacrylamide gels (Invitrogen). Proteins were electrophoretically transferred to Immobilon-P polyvinylidene difluoride membranes (Millipore Wire Test. The wire test was performed as described previously (62) . Briefly, animals were handled by the tail and allowed to grasp the middle of a 1.5-mm-thick, 60-cm-long metallic wire with their forelimbs. Animals were then gently lowered so that their hind paws grasped the wire. The mice were then gently turned upside-down along the axis of the wire. Upon release of the animal, a timer was started. The average time until the mouse completely released its grasp and fell down was recorded; animals unable to grasp the wire or incapable of hanging were assigned the maximum time (120 s). Each mouse was tested three times with a 30-s recovery period between tests.
MB
Observer-Rated Ataxia Measures. Mice were evaluated and scored for ataxia during a 45-s test according to an established protocol (63) . To assess interrater reliability of the splay and wobble rating scales, mice were rated by one person and also independently rated by a separate observer. The rating scales in Table 1 were used. supplemented with 10% (vol/vol) FBS and 1% penicillin-streptomycin. Cells were then washed twice with PBS solution and fixed for 12 min with 4% (wt/vol) PFA at 4°C then rinsed twice with PBS solution, air-dried in the dark, and mounted with Prolong Gold media containing DAPI (InvitrogenMolecular Probes).
Generation of a Tg
In Vitro Cytotoxicity Assay. Gran B-based killing assays were performed as previously described (55) were selected based on enlarged craniums and hunched posture and were pathologically verified to be tumor-bearing postmortem.
Statistical Analysis. All experiments were performed by an examiner blinded to sample identities, and code was not broken until analyses were completed. Data are presented as the mean ± 1 SEM. In instances of single mean comparisons, t test for independent samples was performed. In instances of multiple mean comparisons, one-way ANOVA was used, followed by post hoc comparison of the means by Student t test. P values of less than 0.05 were considered to be statistically significant.
